Drug Monograph

Drug/Drug Class:	**Duzallo® (lesinurad and allopurinol) film coated tablet /Antihyperuricemic Agents**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Duzallo® is a combination of lesinurad and allopurinol. It is available in doses of 200 mg/200 mg and 200 mg/300 mg of lesinurad/allopurinol respectively.
Manufacturer:	Ironwood Pharmaceuticals, Inc., Cambridge, MA 02142.
Indications:	Duzallo® is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
Costs:	$12.36 per tablet of each strength of Duzallo®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Non-Preferred ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer PharmD
Date: May 9, 2018